Could a drug combo let some esophageal cancer patients skip surgery?
NCT ID NCT07584031
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assigned to either watchful waiting with more chemo-immunotherapy or standard surgery. The main goal is to see if watchful waiting can provide similar 2-year cancer-free survival as surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- New drug duo aims to wipe out esophageal tumors before surgery
- New drug cocktail shows promise against tough esophageal cancer
- New triple therapy hopes to outsmart tough esophageal cancer
- New hope for esophageal cancer patients who failed immunotherapy
- Could a new staging system better predict esophageal cancer outcomes?